Sun Pharmaceutical Industries Ltd reported its financial results for the fourth quarter ended March 31, 2025, revealing a dip in profitability despite strong revenue growth.<\/p>\n
In Q4FY25, Sun Pharma\u2019s consolidated net profit fell by 19% to \u20b92,153.9 crore, compared to \u20b92,658.7 crore in the same quarter last year. The dip in net profit comes even as the company saw solid growth in its overall business operations.<\/p>\n
While the net profit declined, Sun Pharma\u2019s total consolidated revenue from operations rose by 8.1%, reaching \u20b912,958.8 crore during the quarter, up from \u20b911,983 crore in the year-ago period.<\/p>\n
This suggests that while operational performance improved, other cost pressures may have weighed on the bottom line.<\/p>\n
The company\u2019s board has declared a final dividend of \u20b95.50 per share for the financial year FY25. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).<\/p>\n
\n\u201cThe Board has recommended a final dividend of \u20b95.50 per equity share of \u20b91 each,\u201d the company said in a statement.<\/p>\n<\/blockquote>\n
The record date for determining eligible shareholders is set for Monday, 7 July 2025. If approved, the dividend will be paid on or before Friday, 8 August 2025.<\/p>\n
EBITDA Growth Shows Operational Strength<\/h3>\n
Sun Pharma also showed a healthy improvement in its operational earnings. The company\u2019s EBITDA (Earnings Before Interest, Tax, Depreciation and Amortization) grew by 22.4% to \u20b93,715.9 crore in Q4FY25, compared to \u20b93,035.15 crore in the same quarter last year.<\/p>\n
\nEBITDA margins also improved significantly, standing at 28.7%, up from 25.3% YoY, indicating stronger efficiency and profitability from core operations.<\/p>\n<\/blockquote>\n
Stock Performance<\/h3>\n
Despite the mixed earnings report, shares of Sun Pharmaceutical Industries Ltd closed marginally lower in Thursday\u2019s trade. The stock ended the day at \u20b91,724.7 per share on the NSE, down 0.41%.<\/p>\n
This Q4 performance highlights a mixed bag for Sun Pharma \u2014 with strong revenue and EBITDA growth, but declining net profit due to one-time factors. The final dividend announcement and improving operational margins, however, signal the company\u2019s continued focus on delivering value to its shareholders.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sun Pharmaceutical Industries Ltd reported its financial results for the fourth quarter ended March 31, 2025, revealing a dip in profitability despite strong revenue growth. In Q4FY25, Sun Pharma\u2019s consolidated net profit fell by 19% to \u20b92,153.9 crore, compared to \u20b92,658.7 crore in the same quarter last year. The dip in net profit comes even […]<\/p>\n","protected":false},"author":2,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"ppma_author":[1329],"class_list":{"0":"post-9191","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-political-news"}," _eael_post_view_count":0,"authors":[{"term_id":1329,"user_id":2,"is_guest":0,"slug":"snehagandhi","display_name":"Sneha Gandhi","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/10\/Sneha-Gandhi.jpeg","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/10\/Sneha-Gandhi.jpeg"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/9191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=9191"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/9191\/revisions"}],"predecessor-version":[{"id":9193,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/9191\/revisions\/9193"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/9192"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=9191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=9191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=9191"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=9191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}